Literature DB >> 12530077

Amplified Muc1-specific gene expression in colon cancer cells utilizing a binary system in adenoviral vectors.

Andreas Block1, Dragan Milasinovic, Juergen Mueller, Peter Schaefer, Hansjoerg Schaefer, Heiner Greten.   

Abstract

Mucin-1 is expressed in a variety of colon carcinomas and Muc-1/DF3 promoters have been utilized to reduce systemic toxicity through specific gene expression. To overcome weak expression, which is much lower than the widely used cytomegalovirus-promoter (CMV), new adenoviral vectors containing a binary system of transgene amplification have been developed. The Muc-1/DF3 promoter was used to control the expression of a Gal4VP16 fusion protein. This vector also contained Gal4 binding sites enabling the fusion protein to act as a transactivator, inducing transgene expression within the same construct. Mucin-1 expression was analyzed in a variety of colon cancer cell lines. After infection with recombinant adenoviruses, transgene expression was quantified using the luciferase system. Integration of the Gal4VP16-binary resulted in an up to 250-fold increase of Muc-1/DF3-specific gene expression. In mucin-positive cell lines utilizing this amplified Muc-1/DF3 promoter, expression was up to 590-fold higher as compared to the CMV-promoter. Western blot detected the presence of Gal4VP16 in infected muc-1-positive but not-negative cell lines. These new adenoviral vectors combing highly efficient and specific transgene expression and will contribute to the safety and efficacy of experimental approaches in cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12530077

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

Review 2.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 3.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

Review 4.  Advances in preclinical investigation of prostate cancer gene therapy.

Authors:  Marxa L Figueiredo; Chinghai Kao; Lily Wu
Journal:  Mol Ther       Date:  2007-04-24       Impact factor: 11.454

5.  Presentation of underglycosylated mucin 1 in pancreatic adenocarcinoma (PDAC) at early stages.

Authors:  Su-Tang Lo; Pamela Pantazopouos; Zdravka Medarova; Anna Moore
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

6.  A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo.

Authors:  Frédéric Pouliot; Makoto Sato; Ziyue Karen Jiang; Steve Huyn; Breanne Dw Karanikolas; Lily Wu
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

Review 7.  Transcriptionally targeted gene therapy to detect and treat cancer.

Authors:  Lily Wu; Mai Johnson; Makoto Sato
Journal:  Trends Mol Med       Date:  2003-10       Impact factor: 11.951

8.  A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis.

Authors:  Steven T Huyn; Jeremy B Burton; Makoto Sato; Michael Carey; Sanjiv S Gambhir; Lily Wu
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

9.  Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expression.

Authors:  Jan Woraratanadharm; Semyon Rubinchik; Hong Yu; John Y Dong
Journal:  BMC Biotechnol       Date:  2007-02-12       Impact factor: 2.563

10.  Cloning and characterization of an adenoviral vector for highly efficient and doxycycline-suppressible expression of bioactive human single-chain interleukin 12 in colon cancer.

Authors:  Holger Wulff; Thorsten Krieger; Karen Krüger; Ingrid Stahmer; Friedrich Thaiss; Hansjörg Schäfer; Andreas Block
Journal:  BMC Biotechnol       Date:  2007-06-26       Impact factor: 2.563

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.